

**STATISTICAL COMPENDIUM:
MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2001
NEVADA**

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE ND.3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP

TABLE ND.11. USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS FOR SELECTED DRUG CATEGORIES AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

FOR DUAL ELIGIBLE BENEFICIARIES

- TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE D.3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE D.11. USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS AMONG DUALS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.12. USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.13. USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS FOR SELECTED DRUG CATEGORIES AMONG DUALS, BY BENEFICIARY CHARACTERISTIC

SUPPLEMENTAL TABLES

- SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES
- SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65
- SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER
- SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74
- SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84
- SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLE

- APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES
- APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES
- APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES
- APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE ND.2

CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a,b}
NONDUAL BENEFICIARIES, NEVADA, 2001

Beneficiary Characteristics	No. of Benes						No. of Bene Mos						Other/ Unknown
	All	Aged	Disabled	Adults	Children	Other/ Unknown	All	Aged	Disabled	Adults	Children	Other/ Unknown	
All	97,876	1,000	17,856	26,862	52,156	2	608,274	9,608	171,285	127,248	300,116	17	
Age													
5 and younger	26,586	9	1,043	0	25,534	0	147,325	41	9,293	0	137,991	0	
6-14	24,697	19	2,569	0	22,109	0	159,786	79	25,931	0	133,776	0	
15-20	10,890	8	1,432	4,951	4,497	2	66,857	57	14,111	24,409	28,263	17	
21-44	26,481	36	5,886	20,544	15	0	153,415	165	56,916	96,254	80	0	
45-64	8,185	43	6,779	1,362	1	0	70,572	351	63,653	6,562	6	0	
65-74	612	491	120	1	0	0	6,154	5,013	1,135	6	0	0	
75-84	313	290	22	1	0	0	3,123	2,920	197	6	0	0	
85 and older	112	104	5	3	0	0	1,042	982	49	11	0	0	
Unknown	0	0	0	0	0	0		0	0	0	0	0	
Gender													
Female	57,273	633	9,246	21,839	25,554	1	346,515	6,240	89,996	104,352	145,917	10	
Male	40,379	367	8,605	5,023	26,383	1	260,446	3,368	81,261	22,896	152,914	7	
Unknown	224	0	5	0	219	0	1,313	0	28	0	1,285	0	
Race													
White	56,605	445	11,918	16,255	27,987	0	374,974	4,107	112,918	82,466	175,483	0	
African American	16,994	74	3,478	4,772	8,668	2	97,823	689	34,699	19,207	43,211	17	
Other/unknown	24,277	481	2,460	5,835	15,501	0	135,477	4,812	23,668	25,575	81,422	0	
Use of Nursing Facilities^c													
Entire year	282	69	212	1	0	0	2,714	638	2,075	1	0	0	
Part year	294	41	247	4	2	0	2,887	449	2,386	28	24	0	
None	97,300	890	17,397	26,857	52,154	2	602,673	8,521	166,824	127,219	300,092	17	
Maintenance Assistance Status													
Cash	59,859	912	16,918	18,185	23,844	0	379,797	9,014	162,675	82,280	125,828	0	
Medically needy	0	0	0	0	0	0		0	0	0	0	0	
Poverty-related	24,440	1	9	5,044	19,386	0	128,766	6	70	22,152	106,538	0	
Other/unknown	13,577	87	929	3,633	8,926	2	99,711	588	8,540	22,816	67,750	17	
Managed Care Status													
FFS all year	69,730	999	17,605	16,212	34,912	2	515,637	9,602	169,561	93,935	242,522	17	
FFS part year, with Rx claims	5,943	1	201	2,830	2,911	0	25,813	6	1,412	11,246	13,149	0	
FFS part year, no Rx claims	22,201	0	50	7,818	14,333	0	66,822	0	312	22,065	44,445	0	

Table ND2

Nondual Beneficiaries

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

- a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{a,b}
 NONDUAL BENEFICIARIES, NEVADA, 2001

Beneficiary Characteristics	% with at Least One Rx	Mean No. of Rx	Mean Rx \$	\$ per Rx	Mean \$, All Services	Rx \$ as % of All Services	No. of Beneficiaries
All	36.7 %	5.2	\$336	\$64	\$3,668	9.2 %	97,876
Age							
5 and younger	28.9	1.3	84	65	1,805	4.7	26,586
6-14	30.5	2.3	149	64	2,171	6.9	24,697
15-20	32.6	2.7	210	76	4,713	4.4	10,890
21-44	40.3	5.8	415	72	4,478	9.3	26,481
45-64	69.0	25.8	1,528	59	9,371	16.3	8,185
65-74	75.0	24.6	1,184	48	10,452	11.3	612
75-84	78.3	25.3	1,226	49	9,400	13.0	313
85 and older	79.5	21.5	872	41	12,892	6.8	112
Unknown	0.0	0.0	0	0	0	0.0	0
Basis of Eligibility^c							
Aged	72.0	23.1	1,129	49	9,394	12.0	1,000
Disabled	70.3	20.4	1,447	71	10,495	13.8	17,856
Adults	30.9	1.9	76	40	2,558	3.0	26,862
Children	27.4	1.4	74	54	1,792	4.2	52,156
Unknown	50.0	3.0	611	204	16,869	3.6	2
Gender							
Female	37.8	5.7	328	58	3,559	9.2	57,273
Male	35.1	4.6	349	76	3,835	9.1	40,379
Unknown	31.3	1.1	31	29	1,230	2.5	224
Race							
White	42.3	6.5	426	66	4,186	10.2	56,605
African American	31.9	4.4	285	64	3,514	8.1	16,994
Other/unknown	26.8	2.8	164	59	2,569	6.4	24,277
Use of Nursing Facilities^d							
Entire year	90.1	65.5	3,241	50	48,844	6.6	282
Part year	95.9	59.6	3,067	52	62,575	4.9	294
None	36.3	4.9	320	66	3,359	9.5	97,300
Maintenance Assistance Status							
Cash	40.5	7.2	478	67	4,085	11.7	59,859
Medically needy	0.0	0.0	0	0	0	0.0	0
Poverty related	24.5	0.9	34	39	1,800	1.9	24,440
Other/unknown	41.9	4.3	254	59	5,191	4.9	13,577

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

- a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.
 - b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
 - c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
 - d. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}
 NONDUAL BENEFICIARIES, NEVADA, 2001

Beneficiary Characteristics	Mean No. of Rx	Mean Rx \$	Rx \$ as % of All Services	No. of Rx, % with:					Mean \$, All Services	Benes	Bene Mos	
				None	More than 0, but 1 or Less	More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less				More than 10
All	0.8	\$54	9.2 %	63.3 %	26.5 %	3.9 %	4.3 %	1.6 %	0.4 %	\$590	97,876	608,274
Age												
5 and younger	0.2	15	4.7	71.1	26.9	1.3	0.5	0.1	0.0	326	26,586	147,325
6-14	0.4	23	6.9	69.5	25.9	2.6	1.8	0.2	0.0	336	24,697	159,786
15-20	0.4	34	4.4	67.4	27.2	3.0	2.0	0.4	0.0	768	10,890	66,857
21-44	1.0	72	9.3	59.7	27.7	5.4	5.4	1.6	0.3	773	26,481	153,415
45-64	3.0	177	16.3	31.0	21.8	11.5	21.6	11.4	2.8	1,087	8,185	70,572
65-74	2.4	118	11.3	25.0	27.5	14.5	22.2	8.5	2.3	1,040	612	6,154
75-84	2.5	123	13.0	21.7	24.3	15.7	26.5	9.6	2.2	942	313	3,123
85 and older	2.3	94	6.8	20.5	25.0	20.5	25.9	5.4	2.7	1,386	112	1,042
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Basis of Eligibility^c												
Aged	2.4	118	12.0	28.0	24.8	14.4	22.6	8.0	2.2	978	1,000	9,608
Disabled	2.1	151	13.8	29.7	31.0	12.1	17.9	7.6	1.7	1,094	17,856	171,285
Adults	0.4	16	3.0	69.1	26.1	2.9	1.6	0.3	0.1	540	26,862	127,248
Children	0.2	13	4.2	72.6	25.1	1.5	0.8	0.1	0.0	311	52,156	300,116
Unknown	0.4	72	3.6	50.0	50.0	0.0	0.0	0.0	0.0	1,985	2	17
Gender												
Female	0.9	54	9.2	62.2	27.0	4.0	4.5	1.8	0.5	588	57,273	346,515
Male	0.7	54	9.1	64.9	25.7	3.8	4.1	1.2	0.2	595	40,379	260,446
Unknown	0.2	5	2.5	68.8	30.4	0.4	0.4	0.0	0.0	210	224	1,313
Race												
White	1.0	64	10.2	57.7	29.8	4.7	5.3	2.1	0.5	632	56,605	374,974
African American	0.8	49	8.1	68.1	22.8	3.7	3.8	1.3	0.3	610	16,994	97,823
Other/unknown	0.5	29	6.4	73.2	21.2	2.3	2.5	0.6	0.1	460	24,277	135,477
Use of Nursing Facilities^d												
Entire year	6.8	337	6.6	9.9	5.7	7.4	26.2	33.0	17.7	5,075	282	2,714
Part year	6.1	312	4.9	4.1	12.2	10.2	32.0	28.9	12.6	6,372	294	2,887
None	0.8	52	9.5	63.7	26.6	3.9	4.2	1.4	0.3	542	97,300	602,673
Maintenance Assistance Status												
Cash	1.1	75	11.7	59.5	26.2	5.1	6.2	2.4	0.5	644	59,859	379,797
Medically needy	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Poverty related	0.2	6	1.9	75.5	23.3	0.8	0.3	0.0	0.0	342	24,440	128,766
Other/unknown	0.6	35	4.9	58.1	33.3	4.3	3.4	0.7	0.2	707	13,577	99,711

Table ND4

Nondual Beneficiaries

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

- a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{a, b, c}
 NONDUAL BENEFICIARIES, NEVADA, 2001

Beneficiary Characteristics	All Rx		Patented Brand-Name Drugs		Off-Patent Brand-Name Drugs		Generic Drugs	
	No. of Rx	Rx \$	No. of Rx	Rx \$	No. of Rx	Rx \$	No. of Rx	Rx \$
All	0.8	\$54	0.4	\$41	0.1	\$4	0.4	\$10
		\$ per Rx		\$ per Rx		\$ per Rx		\$ per Rx
Age								
5 and younger	0.2	15	0.1	12	0.0	0	0.1	3
6-14	0.4	23	0.2	19	0.0	1	0.2	3
15-20	0.4	34	0.2	28	0.0	2	0.2	4
21-44	1.0	72	0.4	53	0.1	6	0.5	13
45-64	3.0	177	1.3	129	0.2	14	1.4	34
65-74	2.4	118	1.2	90	0.2	8	1.0	21
75-84	2.5	123	1.3	95	0.1	5	1.1	22
85 and older	2.3	94	1.0	67	0.2	8	1.1	19
Unknown	0.0	0	0.0	0	0.0	0	0.0	0
Basis of Eligibility^d								
Aged	2.4	118	1.2	90	0.2	7	1.0	20
Disabled	2.1	151	1.0	113	0.1	12	1.0	27
Adults	0.4	16	0.2	12	0.0	1	0.2	4
Children	0.2	13	0.1	10	0.0	1	0.1	2
Unknown	0.4	72	0.2	70	0.0	0	0.2	2
Gender								
Female	0.9	54	0.4	41	0.1	4	0.5	10
Male	0.7	54	0.3	41	0.0	4	0.3	10
Unknown	0.2	5	0.1	4	0.0	0	0.1	1
Race								
White	1.0	64	0.4	48	0.1	5	0.5	12
African American	0.8	49	0.3	38	0.0	3	0.4	9
Other/unknown	0.5	29	0.2	23	0.0	2	0.2	5
Use of Nursing Facilities^e								
Entire year	6.8	337	2.7	233	0.5	23	3.6	79
Part year	6.1	312	2.4	215	0.5	25	3.2	71
None	0.8	52	0.4	39	0.1	4	0.4	9
Maintenance Assistance								
Status								
Cash	1.1	75	0.5	56	0.1	6	0.5	14
Medically needy	0.0	0	0.0	0	0.0	0	0.0	0
Poverty related	0.2	6	0.1	5	0.0	0	0.1	1
Other/unknown	0.6	35	0.3	27	0.0	2	0.3	5

Table ND5

Nondual Beneficiaries

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

- a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Nevada, 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all combined. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}
 NONDUAL BENEFICIARIES, NEVADA, 2001

Therapeutic Category	No. of Rx per Bene Mo among Users			\$ per Bene Mo among Users			\$ per Rx			Users							
	Total	Patented	Off-Patent	Generic	Total	Patented	Off-Patent	Generic	Total No. of Rx	Total Rx \$	No.	As % of All Benes	No. of Bene Mos				
														Brand-Name	Brand-Name	Brand-Name	Brand-Name
Anti-infective Agents	0.3	0.1	0.0	0.1	\$18	\$15	\$0	\$2	\$68	\$117	\$146	\$16	54,180	\$3,685,602	21,786	22.3 %	210,262
Biologics	0.2	0.2	0.0	0.0	242	229	0	13	1004	972	0	2,262	850	853,195	340	0.3	3,519
Antineoplastic Agents	0.5	0.2	0.1	0.2	110	92	7	12	228	417	129	56	1,586	361,589	321	0.3	3,277
Endocrine/Metabolic Drugs	0.6	0.3	0.1	0.2	24	20	2	3	43	64	27	15	44,956	1,916,174	7,766	7.9	78,303
Cardiovascular Agents	1.1	0.5	0.1	0.5	40	27	2	11	38	59	34	20	67,039	2,527,387	6,101	6.2	63,427
Respiratory Agents	0.4	0.2	0.0	0.2	20	15	0	4	47	66	31	23	60,818	2,831,595	14,363	14.7	140,170
Gastrointestinal Agents	0.5	0.3	0.0	0.2	46	38	4	5	95	131	112	29	22,480	2,140,896	4,520	4.6	46,644
Genitourinary Agents	0.2	0.2	0.0	0.1	11	9	0	1	43	54	39	18	5,013	217,577	2,105	2.2	20,507
CNS Drugs	0.9	0.4	0.1	0.4	82	63	10	10	90	143	130	25	89,844	8,108,657	9,529	9.7	98,480
Stimulants/Anti-obesity/Anorexia	0.5	0.4	0.0	0.1	34	26	2	6	64	75	52	40	8,080	516,646	1,388	1.4	15,061
Miscellaneous Psychological/Neurological Agents	0.3	0.2	0.0	0.1	32	28	0	3	111	130	130	50	652	72,559	209	0.2	2,289
Analgesics and Anesthetics	0.5	0.1	0.0	0.4	31	20	3	8	60	148	107	22	66,993	4,015,850	13,352	13.6	130,618
Neuromuscular Agents	0.7	0.3	0.1	0.4	46	34	3	9	64	119	54	24	46,811	2,975,268	6,112	6.2	64,064
Nutritional Products	0.3	0.0	0.1	0.2	5	0	2	2	16	15	24	12	11,824	183,494	4,350	4.4	40,644
Hematological Agents	0.6	0.2	0.1	0.3	121	73	3	45	206	401	30	144	6,657	1,372,140	1,074	1.1	11,354
Topical Products	0.2	0.1	0.0	0.1	8	5	1	2	36	60	42	18	20,192	722,481	9,375	9.6	93,919
Miscellaneous Products	0.5	0.2	0.0	0.3	106	89	5	13	217	451	207	47	1,635	354,415	314	0.3	3,333
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	9	0	0	0	41	0	0	0	1,239	51,240	505	0.5	5,496
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	510,849	32,906,765	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2001. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Nevada, 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c}
 NONDUAL BENEFICIARIES, NEVADA, 2001

Top 10 Drug Groups	Users				Among Users		
	Total Medicaid Rx \$	No. As % of All Benes	No. of Bene Mos	No. of Rx per Bene Mo	\$ per Rx	Rx \$ per Bene Mo	
ANTIPSYCHOTICS	\$4,693,327	4.342	48,098	0.6	\$175	\$98	
ANALGESICS - Narcotic	2,659,340	14.1	140,927	0.3	58	19	
ANTIDEPRESSANTS	2,652,287	7.7	80,674	0.5	71	33	
ANTICONVULSANT	2,515,131	4.6	49,438	0.6	81	51	
ULCER DRUGS	1,720,010	4.4	45,708	0.4	96	38	
ANTIASTHMATIC	1,475,380	9.5	95,297	0.3	48	15	
ANTIVIRAL	1,444,485	1.2	12,443	0.4	300	116	
ANALGESICS - ANTI-INFLAMMATORY	970,082	6.6	66,785	0.2	59	15	
ANTIDIABETIC	903,216	2.7	28,501	0.6	52	32	
PASSIVE IMMUNIZING AGENTS	805,965	119	1,079	0.5	1,473	747	
Total	19,839,223	54,221	568,950	n.a.	n.a.	n.a.	

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2001. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7A
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED
 AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BOE, AND AGE^{a,b,c}
 NONDUAL BENEFICIARIES, NEVADA, 2001

Beneficiary Characteristics	All Top 10 Drug Groups				ANTIPSYCHOTICS				ANALGESICS - Narcotic			
	No. of Rx	Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
All	228,904	\$19,839,223	4,342	4.4 %	48,098	0.6	\$98	13,781	14.1 %	140,927	0.3	\$19
Female	142,732	11,101,610	2,212	3.9	24,305	0.5	82	9,748	17.0	99,198	0.3	18
Disabled	108,951	9,169,447	1,705	18.4	19,164	0.5	92	5,148	55.7	57,431	0.4	27
5 and younger	1,003	177,571	4	0.9	48	0.6	64	27	5.9	296	0.1	1
6-14	3,006	222,845	75	8.3	863	0.4	67	78	8.6	905	0.1	3
15-20	3,010	277,763	88	14.7	946	0.5	66	158	26.4	1,811	0.2	13
21-44	37,292	3,462,442	796	24.3	8,906	0.5	98	2,029	62.0	22,632	0.4	26
45-64	63,673	4,988,960	727	18.6	8,231	0.6	91	2,813	71.8	31,286	0.4	30
65-74	797	49,738	15	20.8	170	0.5	77	36	50.0	417	0.3	7
75-84	140	7,750	0	0.0	0	0.0	0	6	40.0	72	0.4	11
85 and older	30	2,378	0	0.0	0	0.0	0	1	20.0	12	0.1	1
Other Eligibles	33,781	1,932,163	507	1.1	5,141	0.4	46	4,600	9.6	41,767	0.2	5
5 and younger	1,867	218,323	5	0.0	52	0.6	62	146	1.2	1,411	0.1	1
6-14	4,198	263,323	116	1.1	1,268	0.4	61	309	2.8	3,154	0.1	2
15-20	3,606	216,646	102	1.6	1,108	0.4	51	634	10.0	5,741	0.2	2
21-44	16,455	754,728	222	1.3	2,042	0.3	29	3,099	18.2	27,181	0.2	5
45-64	1,920	133,877	12	1.3	108	0.2	15	191	20.7	1,776	0.4	19
65-74	3,875	233,131	36	11.5	425	0.6	65	127	40.4	1,471	0.5	18
75-84	1,556	97,303	13	7.3	126	0.8	81	70	39.1	765	0.3	8
85 and older	304	14,832	1	1.4	12	0.2	16	24	33.3	268	0.2	5
Male	86,140	8,734,923	2,130	5.3	23,793	0.6	114	4,032	10.0	41,725	0.3	22
Disabled	67,621	7,098,722	1,574	18.3	17,699	0.6	122	2,642	30.7	28,568	0.4	30
5 and younger	1,618	365,396	9	1.6	91	0.5	33	34	5.9	391	0.1	1
6-14	6,937	686,539	252	15.2	2,872	0.5	87	143	8.6	1,672	0.1	1
15-20	4,018	413,200	182	21.8	2,059	0.5	104	114	13.7	1,312	0.2	7
21-44	25,104	3,076,144	759	29.0	8,551	0.7	144	955	36.5	10,316	0.4	29
45-64	29,567	2,538,785	367	12.8	4,085	0.7	112	1,370	47.9	14,640	0.5	38
65-74	359	17,894	4	8.3	38	0.4	7	24	50.0	228	0.5	12
75-84	18	764	1	14.3	3	0.3	3	2	28.6	9	0.4	7
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	18,519	1,636,201	556	1.7	6,094	0.5	90	1,390	4.4	13,157	0.2	4
5 and younger	2,560	334,314	21	0.2	233	0.4	94	228	1.7	2,277	0.1	1
6-14	7,892	727,122	339	3.0	3,808	0.5	93	336	3.0	3,418	0.1	1
15-20	3,105	313,076	147	4.7	1,619	0.5	98	231	7.5	2,313	0.1	2
21-44	2,126	92,622	20	0.6	157	0.2	17	423	11.9	3,454	0.2	6
45-64	872	55,540	6	1.2	57	0.4	9	83	17.1	730	0.4	11
65-74	735	42,025	5	2.8	45	0.1	26	35	19.7	392	0.2	6
75-84	826	52,822	11	9.8	119	0.5	93	38	33.9	438	0.2	5
85 and older	403	18,680	7	20.0	56	0.4	39	16	45.7	135	0.6	21
Unknown	32	2,690	0	0.0	0	0.0	0	1	0.4	4	0.3	3

Table ND7A

Nondual Beneficiaries

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2001. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BOE, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, NEVADA, 2001

Beneficiary Characteristics	ANTIDEPRESSANTS					ANTICONVULSANT					ULCER DRUGS				
	No. of Users	Users as % of All Benes	No. of Bene Mos among	Mean Rx	Mean No. of Rx	No. of Users	Users as % of All Benes	No. of Bene Mos among	Mean Rx	Mean No. of Rx	No. of Users	Users as % of All Benes	No. of Bene Mos among	Mean Rx	Mean No. of Rx
All	7,569	7.7 %	80,674	\$33	0.5	4,534	4.6 %	49,438	\$51	0.6	4,311	4.4 %	45,708	\$38	0.4
Female	5,170	9.0	54,652	33	0.5	2,529	4.4	27,363	48	0.6	2,902	5.1	30,936	39	0.4
Disabled	3,341	36.1	37,228	37	0.5	2,017	21.8	22,475	51	0.6	2,091	22.6	23,213	44	0.4
5 and younger	1	0.2	12	30	0.2	30	6.5	323	34	0.8	25	5.4	254	14	0.4
6-14	52	5.7	589	30	0.5	158	17.4	1,766	51	0.7	31	3.4	350	19	0.3
15-20	115	19.2	1,272	33	0.4	112	18.7	1,244	75	0.7	44	7.4	490	22	0.3
21-44	1,340	40.9	14,865	36	0.5	893	27.3	9,882	55	0.6	634	19.4	7,039	41	0.4
45-64	1,818	46.4	20,314	37	0.5	819	20.9	9,203	43	0.6	1,332	34.0	14,801	47	0.5
65-74	13	18.1	152	29	0.4	5	6.9	57	58	0.7	19	26.4	207	26	0.3
75-84	2	13.3	24	58	1.0	0	0.0	0	0	0.0	4	26.7	48	11	0.1
85 and older	0	0.0	0	0	0.0	0	0.0	0	0	0.0	2	40.0	24	0.6	0.4
Other Eligibles	1,829	3.8	17,424	24	0.4	512	1.1	4,888	34	0.5	811	1.7	7,723	24	0.3
5 and younger	10	0.1	113	15	0.3	29	0.2	277	48	0.6	43	0.3	357	8	0.2
6-14	208	1.9	2,263	26	0.4	87	0.8	883	37	0.5	62	0.6	634	11	0.2
15-20	244	3.8	2,620	25	0.3	78	1.2	789	56	0.4	73	1.1	691	14	0.2
21-44	1,156	6.8	10,405	23	0.3	252	1.5	2,248	26	0.4	396	2.3	3,586	21	0.2
45-64	133	14.4	1,152	22	0.3	21	2.3	197	22	0.5	69	7.5	571	29	0.3
65-74	48	15.3	532	38	0.6	34	10.8	375	28	0.8	97	30.9	1,092	42	0.5
75-84	24	13.4	275	22	0.4	9	5.0	95	19	0.5	54	30.2	611	43	0.5
85 and older	6	8.3	64	16	0.4	2	2.8	24	11	0.6	17	23.6	181	18	0.3
Male	2,399	5.9	26,022	34	0.5	2,005	5.0	22,075	55	0.7	1,408	3.5	14,760	35	0.4
Disabled	1,655	19.2	18,242	35	0.5	1,642	19.1	18,300	57	0.7	1,078	12.5	11,648	38	0.4
5 and younger	8	1.4	91	6	0.2	49	8.5	569	47	0.6	48	8.3	539	18	0.4
6-14	208	12.5	2,332	32	0.4	312	18.8	3,563	54	0.6	59	3.5	666	24	0.4
15-20	137	16.4	1,567	36	0.5	158	18.9	1,778	58	0.7	46	5.5	513	18	0.3
21-44	654	25.0	7,198	39	0.5	677	25.9	7,555	68	0.8	326	12.5	3,619	34	0.4
45-64	640	22.4	6,987	32	0.5	439	15.3	4,758	43	0.6	588	20.5	6,224	45	0.5
65-74	7	14.6	61	60	0.5	7	14.6	77	81	1.0	10	20.8	84	28	0.5
75-84	1	14.3	6	2	0.3	0	0.0	0	0	0.0	1	14.3	3	74	0.3
85 and older	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0
Other Eligibles	744	2.3	7,780	30	0.4	363	1.1	3,775	45	0.5	330	1.0	3,112	26	0.3
5 and younger	17	0.1	193	27	0.4	35	0.3	352	24	0.5	44	0.3	397	26	0.3
6-14	427	3.8	4,682	29	0.4	173	1.5	1,901	43	0.5	53	0.5	560	19	0.2
15-20	162	5.2	1,740	33	0.4	86	2.8	915	70	0.5	40	1.3	416	12	0.2
21-44	99	2.8	783	20	0.3	43	1.2	337	23	0.4	90	2.5	686	31	0.3
45-64	21	4.3	178	40	0.4	7	1.4	66	37	0.7	32	6.6	284	36	0.3
65-74	7	3.9	75	41	0.5	8	4.5	80	19	0.3	27	15.2	301	25	0.3
75-84	10	8.9	117	41	0.6	6	5.4	72	34	0.7	31	27.7	350	34	0.4
85 and older	1	2.9	12	59	0.8	5	14.3	52	31	1.1	13	37.1	118	43	0.8
Unknown	0	0.0	0	0	0.0	0	0.0	0	0	0.0	1	0.4	12	2	0.1

Table ND7B

Nondual Beneficiaries

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

- a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2001. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BOE, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, NEVADA, 2001

Beneficiary Characteristics	ANTI-ASTHMATIC				ANTIVIRAL				ANALGESICS - ANTI-INFLAMMATORY						
	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
All	9,266	9.5 %	95,297	0.3	\$16	1,177	1.2 %	12,443	0.4	\$116	6,448	6.6 %	66,785	0.2	\$15
Female	5,390	9.4	55,725	0.3	16	631	1.1	6,734	0.3	81	4,773	8.3	49,457	0.2	15
Disabled	2,959	32.0	32,829	0.4	20	394	4.3	4,413	0.4	105	2,644	28.6	29,784	0.3	20
5 and younger	154	33.6	1,706	0.3	14	8	1.7	89	0.2	15	8	1.7	86	0.1	1
6-14	197	21.7	2,252	0.2	11	22	2.4	261	0.3	67	30	3.3	354	0.1	2
15-20	95	15.9	1,057	0.4	24	12	2.0	138	0.2	23	72	12.0	821	0.2	18
21-44	803	24.5	8,985	0.4	17	185	5.7	2,013	0.4	111	983	30.0	10,367	0.2	14
45-64	1,678	42.8	18,466	0.4	23	166	4.2	1,900	0.4	114	1,511	38.6	17,099	0.3	25
65-74	25	34.7	279	0.7	30	0	0.0	0	0.0	0	27	37.5	301	0.2	14
75-84	5	33.3	60	0.3	13	1	6.7	12	0.1	6	11	73.3	132	0.3	17
85 and older	2	40.0	24	0.1	16	0	0.0	0	0.0	0	2	40.0	24	0.5	42
Other Eligibles	2,431	5.1	22,896	0.2	10	237	0.5	2,321	0.2	37	2,129	4.4	19,673	0.2	8
5 and younger	683	5.6	6,351	0.2	7	31	0.3	313	0.3	33	78	0.6	649	0.1	2
6-14	583	5.4	5,788	0.3	13	18	0.2	202	0.1	4	99	0.9	1,010	0.1	2
15-20	214	3.4	2,021	0.2	9	30	0.5	276	0.2	15	318	5.0	2,971	0.1	2
21-44	744	4.4	6,610	0.3	10	135	0.8	1,294	0.2	35	1,298	7.6	11,455	0.2	5
45-64	78	8.5	692	0.3	11	10	1.1	88	0.3	268	102	11.1	881	0.3	17
65-74	90	28.7	1,020	0.4	19	7	2.2	76	0.1	7	139	44.3	1,621	0.4	27
75-84	25	14.0	252	0.3	16	6	3.4	72	0.1	6	72	40.2	816	0.3	27
85 and older	14	19.4	162	0.2	14	0	0.0	0	0.0	0	23	31.9	270	0.3	14
Male	3,856	9.5	39,395	0.3	15	545	1.3	5,697	0.5	158	1,675	4.1	17,328	0.2	12
Disabled	1,836	21.3	19,955	0.4	19	486	5.6	5,139	0.5	169	1,138	13.2	12,426	0.3	15
5 and younger	257	44.4	2,834	0.3	17	8	1.4	88	0.3	63	6	1.0	68	0.1	1
6-14	425	25.6	4,868	0.3	16	29	1.7	333	0.5	139	45	2.7	488	0.1	16
15-20	109	13.1	1,237	0.3	12	4	0.5	48	0.1	4	56	6.7	645	0.1	5
21-44	284	10.9	3,042	0.4	13	286	10.9	2,929	0.5	163	423	16.2	4,650	0.2	12
45-64	749	26.2	7,915	0.5	25	158	5.5	1,735	0.6	194	598	20.9	6,475	0.3	18
65-74	11	22.9	56	0.6	14	0	0.0	0	0.0	0	9	18.8	92	0.1	6
75-84	1	14.3	3	0.3	4	1	14.3	6	0.2	3	1	14.3	8	0.3	35
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	2,020	6.4	19,440	0.2	11	59	0.2	558	0.3	55	537	1.7	4,902	0.2	7
5 and younger	911	7.0	8,569	0.2	9	16	0.1	143	0.1	4	57	0.4	456	0.1	2
6-14	757	6.7	7,532	0.3	13	25	0.2	248	0.5	66	88	0.8	863	0.1	2
15-20	168	5.4	1,694	0.3	12	5	0.2	43	0.3	26	112	3.6	1,075	0.1	2
21-44	84	2.4	697	0.2	9	10	0.3	88	0.1	21	173	4.9	1,405	0.2	8
45-64	35	7.2	314	0.3	15	2	0.4	24	1.4	446	37	7.6	302	0.2	9
65-74	39	21.9	427	0.4	21	1	0.6	12	0.2	6	27	15.2	321	0.4	22
75-84	18	16.1	162	0.3	12	0	0.0	0	0.0	0	31	27.7	352	0.3	18
85 and older	8	22.9	45	0.3	11	0	0.0	0	0.0	0	12	34.3	128	0.5	29
Unknown	20	8.9	177	0.2	2	1	0.4	12	0.1	2	0	0.0	0	0.0	0

Table ND7C
 Nondual Beneficiaries

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

- a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2001. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BOE, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, NEVADA, 2001

Beneficiary Characteristics	ANTIDIABETIC				PASSIVE IMMUNIZING AGENTS				No. of Bene Mos			
	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users		Mean No. of Rx	Mean Rx \$	No. of Bene Mos
All	2,674	2.7 %	28,501	0.6	\$32	119	0.1 %	1,079	0.5	\$747	97,876	608,274
Female	1,779	3.1	19,143	0.6	32	53	0.1	459	0.5	617	57,273	346,515
Disabled	1,408	15.2	15,588	0.6	32	21	0.2	207	0.5	692	9,246	89,996
5 and younger	0	0.0	0	0.0	0	17	3.7	159	0.6	840	459	3,933
6-14	10	1.1	120	0.9	35	2	0.2	24	0.1	64	907	9,016
15-20	8	1.3	88	0.5	38	0	0.0	0	0.0	0	598	5,827
21-44	297	9.1	3,294	0.6	31	2	0.1	24	0.1	342	3,273	32,150
45-64	1,059	27.0	11,720	0.6	33	0	0.0	0	0.0	0	3,917	38,144
65-74	29	40.3	306	0.5	26	0	0.0	0	0.0	0	72	715
75-84	5	33.3	60	0.5	32	0	0.0	0	0.0	0	15	162
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	5	49
Other Eligibles	371	0.8	3,555	0.6	29	32	0.1	252	0.5	554	48,027	256,519
5 and younger	1	0.0	11	1.5	49	32	0.3	252	0.5	554	12,290	65,958
6-14	20	0.2	211	0.6	28	0	0.0	0	0.0	0	10,861	65,410
15-20	4	0.1	32	1.2	48	0	0.0	0	0.0	0	6,360	33,510
21-44	127	0.7	969	0.6	25	0	0.0	0	0.0	0	17,029	81,305
45-64	41	4.4	360	0.5	20	0	0.0	0	0.0	0	922	4,518
65-74	124	39.5	1,377	0.6	29	0	0.0	0	0.0	0	314	3,310
75-84	49	27.4	535	0.7	38	0	0.0	0	0.0	0	179	1,830
85 and older	5	6.9	60	0.6	41	0	0.0	0	0.0	0	72	678
Male	895	2.2	9,358	0.6	32	65	0.2	608	0.5	857	40,379	260,446
Disabled	706	8.2	7,684	0.6	32	31	0.4	312	0.5	932	8,605	81,261
5 and younger	1	0.2	12	0.8	27	30	5.2	308	0.5	885	579	5,332
6-14	5	0.3	59	1.0	60	1	0.1	4	0.8	4,568	1,662	16,915
15-20	12	1.4	142	0.6	32	0	0.0	0	0.0	0	834	8,284
21-44	143	5.5	1,578	0.7	37	0	0.0	0	0.0	0	2,613	24,766
45-64	535	18.7	5,815	0.6	30	0	0.0	0	0.0	0	2,862	25,509
65-74	8	16.7	66	0.6	21	0	0.0	0	0.0	0	48	420
75-84	2	28.6	12	0.5	12	0	0.0	0	0.0	0	7	35
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Other Eligibles	189	0.6	1,674	0.6	31	34	0.1	296	0.6	777	31,774	179,185
5 and younger	2	0.0	17	0.8	49	33	0.3	284	0.5	741	13,034	70,789
6-14	21	0.2	170	0.9	50	1	0.0	12	1.0	1,639	11,267	68,445
15-20	5	0.2	59	0.8	39	0	0.0	0	0.0	0	3,098	19,236
21-44	45	1.3	310	0.5	19	0	0.0	0	0.0	0	3,566	15,194
45-64	37	7.6	276	0.5	33	0	0.0	0	0.0	0	484	2,401
65-74	30	16.9	326	0.6	32	0	0.0	0	0.0	0	178	1,709
75-84	37	33.0	382	0.6	31	0	0.0	0	0.0	0	112	1,096
85 and older	12	34.3	134	0.5	16	0	0.0	0	0.0	0	35	315
Unknown	0	0.0	0	0.0	0	1	0.4	12	0.2	184	224	1,313

Table ND7D

Nondual Beneficiaries

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

- a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2001. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.8
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BENEFICIARY CHARACTERISTIC^{a, b}
 NONDUAL BENEFICIARIES, NEVADA, 2001

Beneficiary Characteristics	Rx \$ per Bene Mo	No. of Rx per Bene Mo	No. of All-Year NF Residents	Bene Mos among All-Year NF Residents
All	\$337	6.8	282	2,714
Age				
0-64	352	6.9	209	2,037
65-74	365	7.9	33	323
75-84	298	5.9	24	208
85 and older	120	4.1	16	146
Unknown	0	0.0	0	0
Gender				
Female	317	7.1	146	1,463
Male	360	6.4	136	1,251
Unknown	0	0.0	0	0
Race				
White	334	6.8	221	2,100
African American	281	5.9	27	287
Other/unknown	404	7.5	34	327
Basis of Eligibility^c				
Aged	293	6.3	69	638
Disabled	350	7.0	212	2,075
Adults	0	0.0	1	1
Children	0	0.0	0	0
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2001 Medicaid enrollment. A total of 294 beneficiaries who were in nursing facilities for part of their enrollment and their 2,887 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.9
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d, e}
 NONDUAL BENEFICIARIES, NEVADA, 2001

Therapeutic Category	No. of Rx per Bene Mo among Users			\$ per Bene Mo among Users			Total # of Rx			Total Rx \$			Users					
	Patented			Off-Patent			Generic			Patented			Off-Patent			Generic		
	Total	Brand-Name	Off-Patent	Brand-Name	Off-Patent	Generic	Total	Brand-Name	Off-Patent	Brand-Name	Off-Patent	Generic	Total # of Rx	Total Rx \$	No.	As % of All-Year NF Residents	No. of Bene Mos	
Anti-infective Agents	0.5	0.3	0.0	0.2	\$48	\$35	\$4	\$10	\$101	\$127	\$168	\$54	913	\$92,319	182	64.5 %	1,918	
Biologicals	0.1	0.1	0.0	0.0	1	1	0	0	12	12	0	37	50	604	50	17.7	582	
Antineoplastic Agents	0.5	0.1	0.2	0.2	103	44	37	21	187	455	160	97	73	13,677	14	5.0	133	
Endocrine/Metabolic Drugs	1.1	0.6	0.0	0.5	38	31	1	6	33	51	27	12	1,111	36,863	97	34.4	971	
Cardiovascular Agents	1.7	0.6	0.1	1.0	49	30	3	16	28	47	24	16	2,512	70,958	141	50.0	1,446	
Respiratory Agents	0.9	0.3	0.0	0.6	33	17	0	16	36	53	36	27	1,217	44,047	128	45.4	1,347	
Gastrointestinal Agents	1.1	0.5	0.0	0.6	63	49	1	13	55	102	33	20	1,536	84,257	131	46.5	1,344	
Genitourinary Agents	0.6	0.4	0.0	0.2	27	23	0	4	44	59	0	18	306	13,378	45	16.0	494	
CNS Drugs	1.7	0.8	0.1	0.8	130	97	12	20	78	124	111	26	3,260	252,679	184	65.2	1,945	
Stimulants/Anti-obesity/Anorexia	0.0	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0	0.0	0	
Miscellaneous Psychological/Neurological Agents	0.6	0.6	0.0	0.0	50	50	0	0	84	84	0	0	59	4,957	10	3.5	100	
Analgesics and Anesthetics	1.5	0.8	0.1	0.6	64	50	4	10	42	63	32	16	2,233	93,898	138	48.9	1,465	
Neuromuscular Agents	1.6	0.5	0.1	1.0	78	48	3	27	48	93	33	27	2,701	130,366	155	55.0	1,664	
Nutritional Products	0.9	0.0	0.1	0.7	13	0	3	10	15	14	22	14	730	10,832	80	28.4	831	
Hematological Agents	1.4	0.3	0.2	0.9	56	35	2	19	40	135	11	21	876	35,322	66	23.4	636	
Topical Products	0.5	0.2	0.1	0.2	16	10	3	3	34	50	46	16	708	24,056	140	49.6	1,507	
Miscellaneous Products	0.5	0.0	0.0	0.4	11	8	0	3	24	191	0	8	102	2,449	21	7.4	223	
Unknown Therapeutic Category	0.3	0.0	0.0	0.0	12	0	0	0	37	0	0	0	88	3,220	26	9.2	278	
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	18,475	913,882	n.a.	n.a.	n.a.	

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2001. A total of 294 beneficiaries who were in nursing facilities for part of their enrollment and their 2,887 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2001. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003). In Nevada, 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,
 BY TOP-10 DRUG GROUP^{a, b, c, d}
 NONDUAL BENEFICIARIES, NEVADA, 2001

Top 10 Drug Groups in Nursing Facilities	Users				Among Users		
	Total Medicaid Rx \$	No. of Users	As % of All-Year NF Residents	No. of Bene Mos	No. of Rx per Bene Mo	\$ per Rx	Rx \$ per Bene Mo
ANTIPSYCHOTICS	\$144,880	128	45.4 %	1,388	0.8	\$138	\$104
ANTICONVULSANT	109,797	161	57.1	1,777	1.1	54	62
ULCER DRUGS	74,931	136	48.2	1,407	0.8	67	53
ANTIDEPRESSANTS	75,394	116	41.1	1,227	0.8	74	61
ANALGESICS - Narcotic	60,105	159	56.4	1,682	1.0	35	36
ANTIASTHMATIC	29,705	143	50.7	1,425	0.6	35	21
ANALGESICS - ANTI-INFLAMMATORY	29,726	62	22.0	703	0.6	70	42
ANTIANSIETY AGENTS	27,991	106	37.6	1,167	0.7	34	24
ANTI-DIABETIC	25,201	80	28.4	824	0.7	42	31
ANTI-HYPERTENSIVE	24,238	92	32.6	1,011	0.7	34	24
Total	601,968	1,183		12,611	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

- a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2001. A total of 294 beneficiaries who were in nursing facilities for part of their enrollment and their 2,887 benefit months were excluded from the analysis.
 - b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
 - c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
 - d. The top 10 drug groups were determined based on total 2001 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).
- Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, NEVADA, 2001

Beneficiary Characteristics	All Top 10 Drug Groups					ANTIPSYCHOTICS					ANTICONVULSANT						
	No. of Rx	Rx \$	Users as %			Mean Rx \$	No. of Users	Residents	NF	No. of Bene Mos among Users	Mean No. of Rx	Users as %	Residents	NF	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
			128	45.4 %	1,388												
All	10,333	\$601,988	128	45.4 %	1,388	0.8	\$104	161	57.1 %	1,777	1.1	\$62					
Female	5,573	301,197	66	45.2	730	0.7	73	77	52.7	854	1.1	56					
Disabled	3,919	210,038	45	44.6	487	0.6	71	64	63.4	712	1.1	60					
64 or younger	3,830	206,179	42	42.4	451	0.6	71	63	63.6	700	1.1	61					
65-74	89	3,859	3	150.0	36	0.7	69	1	50.0	12	0.4	15					
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0					
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0					
Other Eligibles	1,654	91,159	21	46.7	243	0.8	78	13	28.9	142	1.1	34					
64 or younger	5	132	1	100.0	12	0.1	1	0	0.0	0	0.0	0					
65-74	1,149	64,887	13	61.9	155	0.8	96	12	57.1	137	1.1	33					
75-84	441	23,052	7	46.7	76	0.8	54	1	6.7	5	1.4	46					
85 and older	59	3,088	0	0.0	0	0.0	0	0	0.0	0	0.0	0					
Male	4,760	300,771	62	45.6	658	0.8	139	84	61.8	923	1.2	67					
Disabled	4,170	270,046	50	45.0	549	0.9	146	76	68.5	837	1.2	71					
64 or younger	4,013	261,020	47	44.3	523	0.9	153	73	68.9	801	1.2	68					
65-74	157	9,026	3	75.0	26	0.6	9	3	75.0	36	1.4	140					
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0					
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0					
Other Eligibles	590	30,725	12	48.0	109	0.7	103	8	32.0	86	1.0	28					
64 or younger	68	3,525	3	100.0	30	0.5	13	1	33.3	10	0.6	32					
65-74	64	2,772	0	0.0	0	0.0	0	0	0.0	0	0.0	0					
75-84	208	15,999	5	62.5	49	0.8	184	3	37.5	36	0.8	35					
85 and older	250	8,429	4	50.0	30	0.7	60	4	50.0	40	1.3	22					
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0					

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2001. A total of 294 beneficiaries who were in nursing facilities for part of their enrollment and their 2,887 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2001 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, NEVADA, 2001

Beneficiary Characteristics	ULCER DRUGS						ANTIDEPRESSANTS						ANALGESICS - Narcotic					
	Users as %			Users as %			Users as %			Users as %			Users as %			Users as %		
	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx
All	136	48.2 %	0.8	1,407	0.8	\$53	116	41.1 %	0.8	1,227	0.8	\$61	159	56.4 %	1,682	1.0	\$36	
Female	72	49.3	0.8	778	0.8	57	70	47.9	0.9	727	0.9	58	95	65.1	1,032	0.9	31	
Disabled	50	49.5	0.7	556	0.7	52	52	51.5	0.8	533	0.8	59	64	63.4	695	1.0	37	
64 or younger	50	50.5	0.7	556	0.7	52	52	52.5	0.8	533	0.8	59	63	63.6	683	0.9	37	
65-74	0	0.0	0.0	0	0.0	0	0	0.0	0.0	0	0.0	0	1	50.0	12	1.6	12	
75-84	0	0.0	0.0	0	0.0	0	0	0.0	0.0	0	0.0	0	0	0.0	0	0.0	0	
85 and older	0	0.0	0.0	0	0.0	0	0	0.0	0.0	0	0.0	0	0	0.0	0	0.0	0	
Other Eligibles	22	48.9	1.0	222	1.0	70	18	40.0	1.0	194	1.0	55	31	68.9	337	0.7	19	
64 or younger	0	0.0	0.0	0	0.0	0	0	0.0	0.0	0	0.0	0	2	200.0	24	0.1	3	
65-74	14	66.7	1.0	145	1.0	72	14	66.7	0.9	154	0.9	57	19	90.5	214	1.0	25	
75-84	7	46.7	1.2	65	1.2	78	3	20.0	1.5	28	1.5	63	7	46.7	63	0.5	13	
85 and older	1	12.5	1.0	12	1.0	15	1	12.5	0.8	12	0.8	19	3	37.5	36	0.3	2	
Male	64	47.1	0.8	629	0.8	48	46	33.8	0.8	500	0.8	66	64	47.1	650	1.2	44	
Disabled	54	48.6	0.7	537	0.7	52	41	36.9	0.8	440	0.8	65	60	54.1	621	1.2	44	
64 or younger	51	48.1	0.7	511	0.7	54	39	36.8	0.8	426	0.8	62	58	54.7	617	1.2	44	
65-74	3	75.0	1.0	26	1.0	18	2	50.0	0.9	14	0.9	169	2	50.0	4	2.3	18	
75-84	0	0.0	0.0	0	0.0	0	0	0.0	0.0	0	0.0	0	0	0.0	0	0.0	0	
85 and older	0	0.0	0.0	0	0.0	0	0	0.0	0.0	0	0.0	0	0	0.0	0	0.0	0	
Other Eligibles	10	40.0	0.9	92	0.9	27	5	20.0	0.8	60	0.8	73	4	16.0	29	1.3	49	
64 or younger	0	0.0	0.0	0	0.0	0	0	0.0	0.0	0	0.0	0	0	0.0	0	0.0	0	
65-74	2	33.3	0.5	24	0.5	14	1	16.7	0.9	12	0.9	150	0	0.0	0	0.0	0	
75-84	2	25.0	1.1	24	1.1	53	3	37.5	0.7	36	0.7	51	1	12.5	12	0.5	3	
85 and older	6	75.0	1.0	44	1.0	20	1	12.5	0.8	12	0.8	59	3	37.5	17	1.9	81	
Unknown	0	0.0	0.0	0	0.0	0	0	0.0	0.0	0	0.0	0	0	0.0	0	0.0	0	

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2001. A total of 294 beneficiaries who were in nursing facilities for part of their enrollment and their 2,887 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2001 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, NEVADA, 2001

Beneficiary Characteristics	ANTI-ASTHMATIC					ANALGESICS - ANTI-INFLAMMATORY					ANTI-ANXIETY AGENTS				
	Users as %					Users as %					Users as %				
	No. of Users	No. of Bene NF Residents	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	No. of Bene NF Residents	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	No. of Bene NF Residents	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
All	143	50.7 %	1,425	0.6	\$21	62	22.0 %	703	0.6	\$42	106	37.6 %	1,167	0.7	\$24
Female	76	52.1	841	0.6	17	43	29.5	501	0.6	45	59	40.4	655	0.7	25
Disabled	54	53.5	610	0.7	19	26	25.7	305	0.5	34	41	40.6	440	0.7	23
64 or younger	54	54.5	610	0.7	19	25	25.3	293	0.5	35	39	39.4	416	0.7	24
65-74	0	0.0	0	0.0	0	1	50.0	12	0.5	4	2	100.0	24	0.4	8
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	22	48.9	231	0.3	12	17	37.8	196	0.8	62	18	40.0	215	0.7	30
64 or younger	2	200.0	24	0.1	2	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	17	81.0	178	0.4	15	11	52.4	131	0.8	69	13	61.9	155	0.5	30
75-84	2	13.3	17	0.1	2	5	33.3	53	0.9	58	5	33.3	60	1.0	28
85 and older	1	12.5	12	0.2	3	1	12.5	12	0.1	8	0	0.0	0	0.0	0
Male	67	49.3	584	0.6	26	19	14.0	202	0.5	36	47	34.6	512	0.7	23
Disabled	58	52.3	538	0.7	27	16	14.4	167	0.4	29	42	37.8	454	0.7	24
64 or younger	52	49.1	516	0.6	27	15	14.2	165	0.4	29	40	37.7	440	0.7	25
65-74	6	150.0	22	1.1	22	1	25.0	2	1.0	14	2	50.0	14	0.9	16
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	9	36.0	46	0.4	14	3	12.0	35	1.1	70	5	20.0	58	0.7	10
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	33.3	10	1.0	21
65-74	2	33.3	24	0.4	14	0	0.0	0	0.0	0	1	16.7	12	1.0	8
75-84	2	25.0	13	0.2	4	1	12.5	12	0.8	72	0	0.0	0	0.0	0
85 and older	5	62.5	9	0.8	26	2	25.0	23	1.2	69	3	37.5	36	0.5	7
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2001. A total of 294 beneficiaries who were in nursing facilities for part of their enrollment and their 2,887 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2001 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, NEVADA, 2001

Beneficiary Characteristics	ANTIDIABETIC					ANTIHYPERTENSIVE					Bene Mos among All-Year NF Residents	
	Users as %		No. of Bene		Mean Rx	Users as %		No. of Bene		Mean Rx		
	No. of Users	Residents	NF	Users		NF	Users	No. of Rx	Residents			
All	80	28.4 %	824	0.7	\$31	92	32.6 %	1,011	0.7	\$24	282	2,714
Female	55	37.7	564	0.7	31	46	31.5	489	0.7	22	146	1,463
Disabled	35	34.7	370	0.7	24	26	25.7	277	0.7	20	101	1,020
64 or younger	34	34.3	358	0.7	25	24	24.2	253	0.7	20	99	996
65-74	1	50.0	12	0.9	22	2	100.0	24	0.6	24	2	24
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Other Eligibles	20	44.4	194	0.7	43	20	44.4	212	0.7	24	45	443
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	12
65-74	8	38.1	83	0.6	21	11	52.4	131	0.6	23	21	220
75-84	10	66.7	87	0.7	57	8	53.3	69	0.8	20	15	133
85 and older	2	25.0	24	0.5	70	1	12.5	12	1.0	68	8	78
Male	25	18.4	260	0.8	30	46	33.8	522	0.7	26	136	1,251
Disabled	16	14.4	158	0.8	33	36	32.4	414	0.7	26	111	1,055
64 or younger	15	14.2	156	0.7	33	35	33.0	412	0.7	26	106	1,016
65-74	1	25.0	2	1.5	39	1	25.0	2	1.0	6	4	38
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	1
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Other Eligibles	9	36.0	102	0.9	25	10	40.0	108	0.7	25	25	196
64 or younger	2	66.7	20	1.1	70	2	66.7	20	0.8	61	3	13
65-74	1	16.7	12	1.7	18	0	0.0	0	0.0	0	6	41
75-84	4	50.0	48	0.7	13	5	62.5	60	0.7	18	8	74
85 and older	2	25.0	22	0.9	12	3	37.5	28	0.7	17	8	68
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2001. A total of 294 beneficiaries who were in nursing facilities for part of their enrollment and their 2,887 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2001. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2001 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND10D

Nondual Beneficiaries

TABLE ND.11
 USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS AMONG NONDUALS
 BY BENEFICIARY CHARACTERISTIC^{a,b}
 NEVADA, 2001

Beneficiary Characteristics	No. of Benes with at Least One Part D Excl Rx	% Benes with at Least One Part D Excl Rx	No. of Part D Excl Rx per Bene	Total No. Part D Excl Rx	Total Part D Excl Rx \$	\$ per Part D Excl Rx	Part D Excl Rx \$ as % of All Rx \$	Total No. of Benes
All	11,713	12.0 %	0.5	44,187	\$11,029,260	\$23	3.1 %	97,876
Age								
5 and younger	2,455	9.2	0.2	4,204	63,052	15	2.8	26,586
6-14	1,878	7.6	0.2	3,846	139,847	36	3.8	24,697
15-20	758	7.0	0.2	1,840	56,855	31	2.5	10,890
21-44	3,475	13.1	0.5	13,753	328,830	24	3.0	26,481
45-64	2,807	34.3	2.3	18,575	406,912	22	3.3	8,185
65-74	187	30.6	1.8	1,089	19,296	18	2.7	612
75-84	105	33.5	2.0	640	10,432	16	2.7	313
85 and older	48	42.9	2.1	240	4,036	17	4.1	112
Unknown	0	0.0	0.0	0	0	0	0.0	0
Basis of Eligibility^c								
Aged	311	31.1	1.7	1,749	30,246	17	2.7	1,000
Disabled	5,525	30.9	1.8	32,107	775,722	24	3.0	17,856
Adults	2,022	7.5	0.2	4,414	97,114	22	4.7	26,862
Children	3,855	7.4	0.1	5,917	126,178	21	3.3	52,156
Unknown	0	0.0	0.0	0	0	0	0.0	2
Gender								
Female	7,313	12.8	0.5	29,328	659,500	22	3.5	57,273
Male	4,389	10.9	0.4	14,846	369,570	25	2.6	40,379
Unknown	11	4.9	0.1	13	190	15	2.8	224
Race								
White	7,953	14.1	0.6	32,278	741,394	23	3.1	56,605
African American	1,723	10.1	0.4	6,218	176,761	28	3.7	16,994
Other/unknown	2,037	8.4	0.2	5,691	111,105	20	2.8	24,277
Use of Nursing Facilities^d								
Entire year	162	57.4	6.4	1,800	31,198	17	3.4	282
Part year	206	70.1	5.9	1,749	31,452	18	3.5	294
None	11,345	11.7	0.4	40,638	966,610	24	3.1	97,300
Maintenance Assistance Status								
Cash	8,672	14.5	0.6	37,825	882,442	23	3.1	59,859
Medically needy	0	0.0	0.0	0	0	0	0.0	0
Poverty related	1,453	5.9	0.1	2,019	31,289	15	3.8	24,440
Other/unknown	1,588	11.7	0.3	4,343	115,529	27	3.3	13,577

Table ND11

Nondual Beneficiaries

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

- a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2001.
- b. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12
 USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS AMONG NONDUALS PER BENEFIT MONTH
 BY BENEFICIARY CHARACTERISTIC^{a,b}
 NEVADA, 2001

Beneficiary Characteristics	No. Rx per Bene Mo.	Rx \$ per Bene Mo.	\$ per Rx	Barbiturate \$ per Bene Mo.	Benzodiazepine \$ per Bene Mo.	No. of Bene Mos
All	0.1	\$2	\$23	\$0	\$1	608,274
Age						
5 and younger	0.0	0	15	0	0	147,325
6-14	0.0	1	36	0	0	159,786
15-20	0.0	1	31	0	0	66,857
21-44	0.1	2	24	0	1	153,415
45-64	0.3	6	22	0	3	70,572
65-74	0.2	3	18	0	1	6,154
75-84	0.2	3	16	0	1	3,123
85 and older	0.2	4	17	0	1	1,042
Unknown	0.0	0	0	0	0	0
Basis of Eligibility^c						
Aged	0.2	3	17	0	1	9,608
Disabled	0.2	5	24	0	2	171,285
Adults	0.0	1	22	0	0	127,248
Children	0.0	0	21	0	0	300,116
Unknown	0.0	0	0	0	0	17
Gender						
Female	0.1	2	22	0	1	346,515
Male	0.1	1	25	0	1	260,446
Unknown	0.0	0	15	0	0	1,313
Race						
White	0.1	2	23	0	1	374,974
African American	0.1	2	28	0	0	97,823
Other/unknown	0.0	1	20	0	0	135,477
Use of Nursing Facilities^d						
Entire year	0.7	11	17	1	5	2,714
Part year	0.6	11	18	0	5	2,887
None	0.1	2	24	0	1	602,673
Maintenance Assistance Status						
Cash	0.1	2	23	0	1	379,797
Medically needy	0.0	0	0	0	0	0
Poverty related	0.0	0	15	0	0	128,766
Other/unknown	0.0	1	27	0	0	99,711

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

- a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2001.
- b. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.13
 USE OF AND REIMBURSEMENT FOR PART D EXCLUDED DRUGS FOR SELECTED DRUG CATEGORIES AMONG NONDUALS^{a,b,c}
 NEVADA, 2001

Drug Category	No. Users	Rx \$ per User	Total Rx \$	Rx \$ as % of All Part D Excl Rx \$	Total No. Rx.	\$ per Rx	No. Rx as % of All Part D Excl Rx
All	13,922	\$74	\$1,029,260	100.0 %	44,187	\$23	100.0 %
Anorexia or weight loss/gain	1	819	819	0.1	10	82	0.0
Fertility drugs	0	0	0	0.0	0	0	0.0
Drugs for cosmetic purposes	5	14	72	0.0	6	12	0.0
Cough and cold medications	7,216	45	325,805	31.7	12,099	27	27.4
Vitamins and minerals	1,356	97	131,673	12.8	6,388	21	14.5
Non-prescription drugs	1,177	32	37,919	3.7	3,436	11	7.8
Barbiturates	360	64	23,006	2.2	2,546	9	5.8
Benzodiazepines	3,362	121	407,957	39.6	18,328	22	41.5
Other Part D Excl Rx Drugs	445	229	102,009	9.9	1,374	74	3.1

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

a. Table ND.13 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all non-dual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2001. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2001. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

b. Includes OTC drugs as well as prescription drugs.

c. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility, those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

APPENDIX TABLE A.1

CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b}
NONDUAL BENEFICIARIES, NEVADA, 2001

Beneficiary Characteristics	No. of Beneficiaries					No. of Beneficiaries						
	All	Aged	Disabled	Adults	Children	All	Aged	Disabled	Adults	Children	Unknown	
All	135,967	1,001	17,864	35,017	82,083	2	1,073,508	9,614	172,348	250,610	640,915	21
Age												
5 and younger	41,742	9	1,043	0	40,690	0	313,128	41	9,534	0	303,553	0
6-14	37,741	19	2,569	0	35,153	0	313,526	84	26,225	0	287,217	0
15-20	14,337	8	1,433	6,670	6,224	2	114,269	57	14,172	49,960	50,059	21
21-44	32,520	36	5,891	26,578	15	0	245,466	165	57,211	188,010	80	0
45-64	8,587	43	6,781	1,762	1	0	76,788	351	63,822	12,609	6	0
65-74	612	491	120	1	0	0	6,154	5,013	1,135	6	0	0
75-84	315	291	22	2	0	0	3,130	2,921	197	12	0	0
85 and older	113	104	5	4	0	0	1,047	982	52	13	0	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Gender												
Female	78,874	634	9,249	28,636	40,354	1	620,572	6,241	90,616	208,773	314,930	12
Male	56,772	367	8,610	6,380	41,414	1	451,234	3,373	81,704	41,825	324,323	9
Unknown	321	0	5	1	315	0	1,702	0	28	12	1,662	0
Race												
White	72,893	445	11,921	20,101	40,426	0	569,990	4,107	113,417	139,455	313,011	0
African American	28,466	74	3,482	7,432	17,476	2	241,369	689	35,090	61,031	144,538	21
Other/unknown	34,608	482	2,461	7,484	24,181	0	262,149	4,818	23,841	50,124	183,366	0
Use of Nursing Facilities^c												
Entire year	282	69	212	1	0	0	2,714	638	2,075	1	0	0
Part year	294	41	247	4	2	0	2,916	449	2,412	31	24	0
None	135,391	891	17,405	35,012	82,081	2	1,067,878	8,527	167,861	250,578	640,891	21
Maintenance Assistance Status												
Cash	77,518	913	16,923	23,003	36,679	0	617,265	9,020	163,722	160,674	283,849	0
Medically needy	0	0	0	0	0	0	0	0	0	0	0	0
Poverty related	38,945	1	11	6,538	32,395	0	290,851	6	76	40,006	250,763	0
Other/unknown	19,504	87	930	5,476	13,009	2	165,392	588	8,550	49,930	106,303	21
Managed Care Status												
FFS all year	69,730	999	17,605	16,212	34,912	2	515,633	9,602	169,562	93,922	242,526	21
FFS part year, with Rx claims	5,943	1	201	2,830	2,911	0	53,723	11	2,268	24,601	26,843	0
FFS part year, no Rx claims	22,201	0	50	7,818	14,333	0	186,179	0	493	63,280	122,406	0
MC all year, with Rx claims	667	0	2	135	530	0	4,621	0	14	1,163	3,444	0
MC all year, no Rx claims	37,426	1	6	8,022	29,397	0	313,352	1	11	67,644	245,696	0

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene Mo(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2
MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a
NONDUAL BENEFICIARIES, NEVADA, 2001

	Bene Mos in Cell J of Table 1		Benes and		Included in Cell K of Table 1		Excluded from Cell K of Table 1	
	No. of Benes	No. of Bene Mos	No. of Benes	No. of Bene Mos	No. of Benes	No. of Bene Mos	No. of Benes	No. of Bene Mos
All	135,967	1,073,508	97,876	608,270	37,424	465,238		
FFS all year	69,730	515,633	69,730	515,633	0	0		
FFS part year, with Rx claims	5,943	53,723	5,943	25,813	0	27,910		
FFS part year, with no Rx claims	22,201	186,179	22,201	66,822	0	119,357		
MC all year, with Rx claims	667	4,621	0	0	0	4,621		
MC all year, with no Rx claims	37,426	313,352	2	2	37,424	313,350		

Source: Data for this table are from the MAX 2001 file for Nevada, released by CMS in 07/2005. This table was produced on 09/19/2006.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.